1. Home
  2. BIVI

as of 12-05-2025 2:02pm EST

$1.55
$0.06
-3.73%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Chart Type:
Time Range:
Founded: 2013 Country:
United States
United States
Employees: N/A City: CARSON CITY
Market Cap: 14.2M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 71.9K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -7.08 EPS Growth: N/A
52 Week Low/High: $1.25 - $30.90 Next Earning Date: 11-10-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered BIVI Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 4 days ago

AI Recommendation

hold
Model Accuracy: 72.00%
72.00%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest BioVie Inc. News

BIVI Breaking Stock News: Dive into BIVI Ticker-Specific Updates for Smart Investing

All BIVI News

Share on Social Networks: